Education
About Us
Working with TipRanks
Follow Us
Day One Biopharmaceuticals (DAWN)
NASDAQ:DAWN
DAWN Stock Chart & Stats
$7.92
-$0.14(-1.13%)
At close: 4:00 PM EST
$7.92
-$0.14(-1.13%)
Day’s Range― - ―
52-Week Range$5.64 - $13.92
Previous CloseN/A
Volume175.11K
Average Volume (3M)2.74M
Market Cap
$813.19M
Enterprise Value$280.15M
Total Cash (Recent Filing)$451.58M
Total Debt (Recent Filing)$2.89M
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Mar 09, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding102,675,500
10 Day Avg. Volume1,937,070
30 Day Avg. Volume2,742,776
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.36
Price to Sales (P/S)9.04
P/FCF Ratio-14.78
Enterprise Value/Market Cap0.34
Enterprise Value/Revenue2.10
Enterprise Value/Gross Profit2.34
Enterprise Value/Ebitda-1.98
Forecast
1Y Price Target
$23.75Price Target Upside199.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.03
Revenue Forecast (FY)$148.51M
Bulls Say, Bears Say
Bulls Say
Acquisition StrategyDay One announced a definitive agreement to acquire Mersana for $25 per share in cash, which is viewed as a smart catapult forward for the company.
Product EfficacyThe 3-year follow-up from FIREFLY-1, focusing on rates of tumor growth rebound and tumor stability, could provide significantly greater confidence for prescribers.
Revenue GrowthDay One Biopharmaceuticals reported strong revenue growth for Ojemda, with 3Q25 revenue slightly higher than estimates.
Bears Say
Adverse Effects34% of patients on treatment experienced Grade ≥3 decreased growth velocity, which was a reversible adverse effect.
Asset ValidationA share move reflecting Day One needs to prove the asset's worth due to the history of Mersana’s previous assets.
Investor ConfidenceDAWN stock reacted negatively (~-13%) post the acquisition announcement which could be a reflection of lack of investor confidence in Mersana's pipeline based on prior failures.
Day One Biopharmaceuticals News
DAWN FAQ
What was Day One Biopharmaceuticals’s price range in the past 12 months?
Day One Biopharmaceuticals lowest stock price was $5.63 and its highest was $13.92 in the past 12 months.
What is Day One Biopharmaceuticals’s market cap?
Day One Biopharmaceuticals’s market cap is $813.19M.
When is Day One Biopharmaceuticals’s upcoming earnings report date?
Day One Biopharmaceuticals’s upcoming earnings report date is Mar 09, 2026 which is in 91 days.
How were Day One Biopharmaceuticals’s earnings last quarter?
Day One Biopharmaceuticals released its earnings results on Nov 04, 2025. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.297 by $0.107.
Is Day One Biopharmaceuticals overvalued?
According to Wall Street analysts Day One Biopharmaceuticals’s price is currently Undervalued.
Does Day One Biopharmaceuticals pay dividends?
Day One Biopharmaceuticals does not currently pay dividends.
What is Day One Biopharmaceuticals’s EPS estimate?
Day One Biopharmaceuticals’s EPS estimate is -0.19.
How many shares outstanding does Day One Biopharmaceuticals have?
Day One Biopharmaceuticals has 102,675,500 shares outstanding.
What happened to Day One Biopharmaceuticals’s price movement after its last earnings report?
Day One Biopharmaceuticals reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.297. Following the earnings report the stock price went up 25.205%.
Which hedge fund is a major shareholder of Day One Biopharmaceuticals?
Currently, no hedge funds are holding shares in DAWN
Day One Biopharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.75 (199.87% Upside)
$23.75 (199.87% Upside)
Blogger Sentiment
Bullish
DAWN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 878.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.6%
Last 30 Days ▲ 8.5%
Last 30 Days ▲ 8.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-41.15%
12-Months-Change
Fundamentals
Return on Equity
-30.16%
Trailing 12-Months
Asset Growth
-14.49%
Trailing 12-Months
Company Description
Day One Biopharmaceuticals
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
DAWN Company Deck
DAWN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with strong revenue growth, increased prescriptions, and positive clinical data. The raised revenue guidance and inclusion in NCCN guidelines further support a positive trajectory. However, the high gross-to-net ratio and limited impact of EAP patients were noted challenges.View all DAWN earnings summariesDAWN Stock 12 Month Forecast
Average Price Target
$23.75
▲(199.87% Upside)
Technical Analysis
Theravance Biopharma
―
Kura Oncology
―
Gossamer Bio
―
Maravai Lifesciences Holdings
―
Septerna, Inc.
―
Ownership Overview
4.18% Insiders
21.39% Mutual Funds
28.22% Other Institutional Investors
34.60% Public Companies and
Individual Investors